ProfileGDS5678 / 1443019_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 41% 40% 40% 41% 39% 43% 42% 39% 39% 40% 40% 41% 40% 40% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9796241
GSM967853U87-EV human glioblastoma xenograft - Control 22.9075940
GSM967854U87-EV human glioblastoma xenograft - Control 32.9119240
GSM967855U87-EV human glioblastoma xenograft - Control 42.8988541
GSM967856U87-EV human glioblastoma xenograft - Control 52.8455139
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0799343
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0490642
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8803739
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.867639
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9123740
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9089140
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9100641
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9211240
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9015240